Drug Trial Radar · NCT03485209
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
350
Actual
Start
Jun 25, 2018
Primary completion
Mar 20, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Genmab; Merck Sharp & Dohme LLC
- First posted
- Apr 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, participants will receive tisotumab vedotin every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. * Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin. The objectives of the study have been achieved. Therefore, the study will transition to a long-term extension phase (LTEP). * In LTEP, participants still receiving clinical benefit based on the investigator's assessment and remaining on treatment may continue receiving treatment. * Participants will still receive tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin
Conditions
- Colorectal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Exocrine Pancreatic Cancer
- Carcinoma, Squamous Cell of Head and Neck
Interventions
tisotumab vedotinDrug
Given into the vein (IV; intravenously)
pembrolizumabDrug
200mg or 400mg given by IV
carboplatinDrug
AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
cisplatinDrug
100mg/m\^2 given by IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G)Time frame: Up to approximately 3 years
Locations
175 sites in 7 countries. Site status is shown where the registry gives one.
UCSD Medical Center - Encinitas
Encinitas, California
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
UCSD Koman Family Outpatient Pavilion
La Jolla, California
UC San Diego/Moores Cancer Center
La Jolla, California
UCSD Shiley Eye Institute
La Jolla, California
University of California Davis Medical Center
Sacramento, California
University of California, Davis Comprehensive Cancer Center
Sacramento, California
UC San Diego Medical Center- Hillcrest
San Diego, California
UC San Diego Health - Rancho Bernardo
San Diego, California
Stanford Cancer Center South Bay
San Jose, California
UCSD Medical Center - Vista
Vista, California
Poudre Valley Hospital
Fort Collins, Colorado
Eye Center of Northern Colorado
Fort Collins, Colorado
Cancer Care & Hematology - Fort Collins
Fort Collins, Colorado
Eye Center of Northern Colorado
Fort Collins, Colorado
Cancer Care & Hematology - Greeley
Greeley, Colorado
Cancer Care & Hematology - Loveland
Loveland, Colorado
Simlow Cancer Hospitalat Yale-New Haven
New Haven, Connecticut
Yale-New Haven Hospital- Yale Cancer Center
New Haven, Connecticut
C/O Thomas Ferenez.RPh,BCOP,Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut
Family Focus Eye Care - Gainesville
Gainesville, Florida
UF Health Davis Cancer Pavilion and Shands Med Plaza
Gainesville, Florida
UF Health Shands Cancer Hospital
Gainesville, Florida
UF Health Shands Hospital
Gainesville, Florida
Family Focus Eye Care - Lake City
Lake City, Florida
Moffitt Cancer Center McKinley Hospital
Tampa, Florida
Moffitt Cancer Center
Tampa, Florida
Richard M Schulze Family Foundation Outpatient Center at McKinley Campus
Tampa, Florida
Emory University Hospital Midtown
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
Investigational Drug Service, Emory University Clinic
Atlanta, Georgia
The Emory Clinic
Atlanta, Georgia
Winship Cancer Institute, Emory University
Atlanta, Georgia
Northwestern Medical Group
Chicago, Illinois
Northwestern Memorial Hospital
Chicago, Illinois
UChicago Medicine - River East
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois
Northwestern Medicine Kishwaukee Hospital
DeKalb, Illinois
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.